<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721341</url>
  </required_header>
  <id_info>
    <org_study_id>SABR-COMET 10</org_study_id>
    <nct_id>NCT03721341</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors</brief_title>
  <acronym>SABR-COMET 10</acronym>
  <official_title>A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Palma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amsterdam University Medical Centre, VUmc Site</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Columbia Cancer - Centre for the North</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beaston West of Scotland Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with a limited oligometastatic burden (cancer has spread but is not yet&#xD;
      considered metastatic), emerging evidence suggests that treatment of all sites of disease&#xD;
      with ablative therapies can improve patient outcomes, including overall- and progression-free&#xD;
      survival. The application of Stereotactic Ablative Radiotherapy (SABR) for patients with 4-10&#xD;
      metastatic deposits appears promising, yet it is unclear if all patients with greater than 3&#xD;
      oligometastatic lesions benefit from ablative therapies in terms of improved Overall Survival&#xD;
      (OS), Progression Free Survival (PFS), or quality of life. The purpose of this study is to&#xD;
      assess the impact of SABR, compared to standard of care treatment, on overall survival,&#xD;
      oncologic outcomes, and quality of life in patients with a controlled primary tumor and 4-10&#xD;
      metastatic lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival at Study Completion</measure>
    <time_frame>At approximately end of year 6 (study completion)</time_frame>
    <description>Time from randomization to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>At approximately year 3, and end of year 6 (study completion)</time_frame>
    <description>Time from randomization to disease progression at any site or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to development of new metastatic lesions</measure>
    <time_frame>At approximately end of year 6 (study completion)</time_frame>
    <description>New metastatic lesions will be detected using computed tomography, magnetic resonance imaging, and/or bone scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by the Functional Assessment of Cancer Therapy- General (FACT-G) questionnaire</measure>
    <time_frame>At approximately end of year 6 (study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by the EuroQOL Group EQ-5D-5L questionnaire</measure>
    <time_frame>At approximately end of year 6 (study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity as measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>End of years 1, 2, 3, 4, 5, and 6 (study completion)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at midpoint of Study</measure>
    <time_frame>At approximately year 3 (midpoint)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Metastatic Tumors</condition>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care treatment: palliative radiotherapy, chemotherapy, immunotherapy, hormones, or observation, is at the discretion of the treating oncologist.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic ablative radiotherapy, plus standard of care treatment: chemotherapy, immunotherapy, hormones, or observation given at the discretion of the treating oncologist.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Palliative Radiation</intervention_name>
    <description>Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <other_name>Palliative Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Chemotherapy may be given as indicated.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotherapy</intervention_name>
    <description>Immunotherapy may be given as indicated.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hormones</intervention_name>
    <description>Hormones may be given as indicated.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observation</intervention_name>
    <description>Observation only is acceptable if this is the standard practice.</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Ablative Radiotherapy</intervention_name>
    <description>Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).</description>
    <arm_group_label>Stereotactic Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Willing to provide informed consent&#xD;
&#xD;
          -  Karnofsky performance score greater than 60&#xD;
&#xD;
          -  Life expectancy greater than 6 months&#xD;
&#xD;
          -  Histologically confirmed malignancy with metastatic disease detected on imaging.&#xD;
             Biopsy of metastasis is preferred, but not required.&#xD;
&#xD;
          -  Controlled primary tumor defined as: at least 3 months since original tumor treated&#xD;
             definitively, with no progression at primary site&#xD;
&#xD;
          -  Total number of metastases 4-10&#xD;
&#xD;
          -  All sites of disease can be safely treated based on a pre-plan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious medical comorbidities precluding radiotherapy. These include interstitial lung&#xD;
             disease in patients requiring thoracic radiation, Crohn's disease in patients where&#xD;
             the GI tract will receive radiotherapy, and connective tissue disorders such as lupus&#xD;
             or scleroderma.&#xD;
&#xD;
          -  For patients with liver metastases, moderate/severe liver dysfunction (Child Pugh B or&#xD;
             C)&#xD;
&#xD;
          -  Substantial overlap with a previously treated radiation volume. Prior radiotherapy in&#xD;
             general is allowed, as long as the composite plan meets dose constraints herein. For&#xD;
             patients treated with radiation previously, biological effective dose calculations&#xD;
             should be used to equate previous doses to the tolerance doses listed below. All such&#xD;
             cases must be discussed with one of the study PIs.&#xD;
&#xD;
          -  Malignant pleural effusion&#xD;
&#xD;
          -  Inability to treat all sites of disease&#xD;
&#xD;
          -  Any single metastasis greater than 5 cm in size.&#xD;
&#xD;
          -  Any brain metastasis greater than 3 cm in size or a total volume of brain metastases&#xD;
             greater than 30 cc.&#xD;
&#xD;
          -  Metastasis in the brainstem&#xD;
&#xD;
          -  Clinical or radiologic evidence of spinal cord compression&#xD;
&#xD;
          -  Dominant brain metastasis requiring surgical decompression&#xD;
&#xD;
          -  Metastatic disease that invades any of the following: GI tract (including esophagus,&#xD;
             stomach, small or large bowel), mesenteric lymph nodes, or skin&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Palma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre, Lawson Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suresh Senan, MRCP, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam University Medical Centre, VUmc Site</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Olson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer - Centre for the North</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Harrow, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beaston West of Scotland Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Palma, MD</last_name>
    <phone>519-685-8650</phone>
    <email>David.Palma@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nova Scotia Health Authortiy</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Simpson</last_name>
      <email>Robin.Simpson@nshealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kim Pitts</last_name>
      <email>Kim.Pitts@nshealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Liam Mulroy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Girolametto</last_name>
      <phone>519-749-4300</phone>
      <phone_ext>2307</phone_ext>
      <email>carla.girolametto@grhosp.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Elyse Wellhauser</last_name>
      <phone>519-749-4370</phone>
      <phone_ext>2447</phone_ext>
      <email>Elyse.Wellhauser@grhosp.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Darin Gopaul, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program of the Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Palma, MD</last_name>
      <phone>519-685-8650</phone>
      <email>David.Palma@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>David Palma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trillium Health Partners-Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Health Sciences North</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Ricard</last_name>
      <phone>705-522-6237</phone>
      <phone_ext>2615</phone_ext>
      <email>laricard@hsnsudbury.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Pearce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessy Abed, MRT(T), MHSc.</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>5881</phone_ext>
      <email>Jessy.Abed@rmp.uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>William Tang</last_name>
      <phone>416-946-4501</phone>
      <email>william.tang@RMP.uhn.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Aisling Barry, MRCPI,FFRRCSI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meredith Giuliani, MBBS,FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal-CHUM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Trudel, RN</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>11181</phone_ext>
      <email>diane.dt.trudel.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Chantal Lafleur</last_name>
      <phone>514-890-8000</phone>
      <email>chantal.lafleur.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Houda Bahig</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philip Wong</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Schaefer</last_name>
      <phone>41 44 255 37 68</phone>
      <email>Cornelia.Schaefer@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Matthias Guckenberge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>David Palma</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

